Compare ATLX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | IMUX |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.2M | 85.8M |
| IPO Year | N/A | N/A |
| Metric | ATLX | IMUX |
|---|---|---|
| Price | $5.04 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $6.00 |
| AVG Volume (30 Days) | 546.2K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,454.00 | N/A |
| Revenue This Year | $22,084.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $0.56 |
| 52 Week High | $8.32 | $1.42 |
| Indicator | ATLX | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 44.84 |
| Support Level | $4.50 | $0.67 |
| Resistance Level | $5.15 | $0.73 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 49.35 | 35.64 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project located in Minas Gerais State in Brazil. The company intends to produce and sell lithium concentrate, a key ingredient for the battery supply chain. It intends to mine and then process its lithium-containing ore to produce lithium concentrate (also known as spodumene concentrate), a key ingredient for the battery supply chain.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.